RPS6KA1 and acute myeloid leukemia: The higher efficacy and tendency of compound 24 in AML cells may be attributed to the circumvention of anti-apoptotic mediators, specifically RSK1 and AMPK, with its concurrent pan-Pim kinase inhibitory activity and this also relies on the fact that AZD1708, which is one of the critical selective Pim kinase inhibitors, was less potent than compound 24 versus tested AML cell lines.